TrialClinical pharmacology in drug development2025

First-in-Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN-3143, a Novel Inhibitor of Mono-Adenosine Diphosphate Ribosyltransferase-PARP14.

Thomas M Polasek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.